Zilucoplan for French patients with anti‑AChR myasthenia gravis — three‑month outcomes
Multicenter Retrospective Study on the Short- and Medium-Term Efficacy and Tolerance of Zilucoplan Therapy in a Cohort of French Patients With Anti-AChR Myasthenia Gravis
This project will try Zilucoplan (Zilbrysq) in French patients with anti‑AChR myasthenia gravis to see if muscle strength and quality of life improve over three months while tracking side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 55 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice, Alpes Maritimes) |
| Trial ID | NCT06815133 on ClinicalTrials.gov |
What this trial studies
This is a multicenter retrospective observational review led by CHU Nice that collects real-world data on French patients with anti‑AChR myasthenia gravis treated with Zilucoplan. Investigators will extract baseline characteristics, three-month measures of muscle strength and validated quality-of-life scores, and recorded adverse events from medical records. The analysis focuses on short- and medium-term efficacy and tolerability in routine clinical practice rather than results from randomized controlled trials. The goal is to describe how patients outside of trials respond to Zilucoplan during the first three months of therapy.
Who should consider this trial
Good fit: Ideal candidates are French patients with a confirmed anti‑AChR antibody–positive diagnosis of myasthenia gravis who have been treated with Zilucoplan and have accessible clinical records covering the first three months of therapy.
Not a fit: Patients without anti‑AChR antibodies, those who never received Zilucoplan, or people whose records are unavailable or incomplete are unlikely to be included or to benefit from the study's findings.
Why it matters
Potential benefit: If positive, the findings could support that Zilucoplan provides meaningful short-term improvements in muscle strength and daily functioning with acceptable tolerability for anti‑AChR myasthenia gravis patients.
How similar studies have performed: Prior randomized trials of complement-targeting therapies, including earlier prospective studies of zilucoplan, have shown benefits in anti‑AChR myasthenia gravis, and this retrospective work examines real-world short-term outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Confirmed diagnosis of myasthenia gravis with anti-AChR antibodies in patients treated with Zilucoplan Exclusion Criteria: * None
Where this trial is running
Nice, Alpes Maritimes
- Chu Nice — Nice, Alpes Maritimes, France (Recruiting)
Study contacts
- Study coordinator: Sabrina Sacconi
- Email: sacconi.s@chu-nice.fr
- Phone: 04 92 03 57 57
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.